Taloxa: Uses, Dosage & Side Effects
An antiepileptic drug (felbamate) used for Lennox-Gastaut syndrome and refractory epilepsy in adults and children over 4 years when other treatments have failed
Taloxa (felbamate) is an antiepileptic medication used to treat Lennox-Gastaut syndrome and other severe forms of epilepsy that cannot be adequately controlled with other antiepileptic drugs. It is approved for use in adults and children over 4 years of age, either as adjunctive therapy (alongside other seizure medications) or, in some cases, as monotherapy. Felbamate works through multiple mechanisms, including blocking NMDA receptors, enhancing GABAergic inhibition, and inhibiting sodium channels. Due to rare but serious risks of aplastic anemia and hepatic failure, Taloxa is reserved for patients with refractory epilepsy and requires regular blood monitoring throughout treatment.
Quick Facts: Taloxa
Key Takeaways
- Taloxa (felbamate) is reserved for severe, refractory epilepsy – particularly Lennox-Gastaut syndrome – when other antiepileptic drugs have failed to provide adequate seizure control.
- Due to rare but potentially fatal risks of aplastic anemia and hepatic failure, mandatory blood monitoring (complete blood count and liver function tests) every 1–2 weeks is required throughout treatment.
- Felbamate interacts significantly with other antiepileptic drugs (phenytoin, carbamazepine, valproic acid) and can reduce the effectiveness of oral contraceptives – dose adjustments and alternative contraception may be needed.
- Available as both oral suspension (120 mg/ml) and tablets (600 mg), typically taken 2–3 times daily; the dose is gradually increased during the first weeks of treatment under medical supervision.
- Taloxa should not be used during pregnancy unless absolutely necessary; felbamate passes into breast milk, so breastfeeding is not recommended during treatment.
What Is Taloxa and What Is It Used For?
Taloxa contains the active substance felbamate, a broad-spectrum antiepileptic drug that belongs to the carbamate class of anticonvulsants. It was first approved in the United States in 1993 under the brand name Felbatol and subsequently authorized in Europe. Felbamate occupies a unique position among antiepileptic drugs due to its multiple mechanisms of action, which make it effective against seizure types that are resistant to other therapies. However, due to rare but serious adverse effects identified after initial marketing, its use is now restricted to patients with severe, treatment-resistant epilepsy.
The primary mechanism of action of felbamate involves three complementary pathways. First, it acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically binding to the NR2B subunit. By blocking excessive glutamate-mediated excitatory neurotransmission through NMDA receptors, felbamate reduces the abnormal neuronal hyperexcitability that underlies seizure activity. Second, felbamate enhances inhibitory neurotransmission by modulating gamma-aminobutyric acid type A (GABA-A) receptors, potentiating the effects of the brain’s primary inhibitory neurotransmitter. Third, it blocks voltage-gated sodium channels, which reduces repetitive neuronal firing – a mechanism shared with several other antiepileptic drugs such as carbamazepine and phenytoin. This triple mechanism of action explains why felbamate can be effective in patients whose seizures are not controlled by drugs that target only one of these pathways.
Taloxa is specifically indicated for the treatment of Lennox-Gastaut syndrome (LGS) and other forms of epilepsy that cannot be adequately controlled with other antiepileptic medications. Lennox-Gastaut syndrome is a severe childhood-onset epilepsy syndrome characterized by multiple seizure types (including tonic, atonic, and atypical absence seizures), slow spike-and-wave discharges on electroencephalography (EEG), and often cognitive impairment. LGS is notoriously difficult to treat, and many patients continue to experience frequent seizures despite treatment with multiple antiepileptic drugs. Felbamate has demonstrated particular efficacy in reducing the frequency of atonic seizures (drop attacks) in LGS, which are among the most disabling seizure types due to the high risk of injury from falls.
In clinical trials, felbamate significantly reduced total seizure frequency in patients with Lennox-Gastaut syndrome compared with placebo. The pivotal trial in LGS showed a 34% reduction in total seizure frequency and a 44% reduction in atonic seizures specifically. These results led to its approval as both adjunctive therapy (used alongside other antiepileptic drugs) and, in adults, as monotherapy for partial seizures with or without secondary generalization. The medication is approved for use in adults and children over 4 years of age.
Although felbamate is an effective antiepileptic drug, it is reserved for patients whose epilepsy cannot be controlled by other medications. This is because post-marketing surveillance identified a rare but significant risk of aplastic anemia (estimated at 1 in 3,000–5,000 patients per year) and hepatic failure (estimated at 1 in 10,000–25,000 patients per year). The risk-benefit ratio favors its use only when the severity of the epilepsy justifies the potential for these serious adverse effects. All patients must undergo regular blood monitoring throughout treatment.
What Should You Know Before Taking Taloxa?
Contraindications
Taloxa must not be used in certain circumstances. Understanding these absolute contraindications is essential before starting treatment, as using felbamate in these situations could lead to life-threatening complications.
- Hypersensitivity: Do not take Taloxa if you are allergic to felbamate or any of the other ingredients in the product. Allergic reactions may include rash, fever, swelling of the nose, eyes, or throat, and breathing difficulties. If any of these symptoms occur, seek immediate medical attention.
- History of blood disorders: Do not take Taloxa if you have previously experienced problems with your blood, including anemia (low red blood cells), low white blood cell counts, low platelet counts, bleeding problems, easy bruising, or frequent infections. These conditions indicate potential bone marrow vulnerability, which could be exacerbated by felbamate.
- History of liver problems: Do not take Taloxa if you have had liver disease, including jaundice (yellowing of the eyes or skin) or hepatitis. Pre-existing liver impairment significantly increases the risk of felbamate-associated hepatic failure.
Warnings and Precautions
Taloxa has been associated with rare cases of life-threatening blood disorders (aplastic anemia) and liver failure. Inform your doctor immediately if you experience any unusual symptoms such as bleeding, bruising, frequent infections, fatigue, jaundice (yellow eyes or skin), weight loss, vomiting, or abdominal pain. Your doctor will schedule blood tests every 1–2 weeks to monitor your condition throughout treatment.
Several important precautions apply to patients taking Taloxa. Your healthcare provider should be informed about your complete medical history before starting treatment.
- Allergic and hypersensitivity reactions: Seek immediate medical attention if you develop a rash, fever, or swelling of the nose, eyes, or throat, or if you experience breathing difficulties while taking Taloxa. Rare but severe hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (blistering and peeling of the skin) have been reported.
- Do not stop suddenly: If you have been taking Taloxa or any other antiepileptic medication regularly, do not stop taking it without your doctor’s guidance. Sudden withdrawal of antiepileptic drugs can trigger increased seizure frequency, including potentially dangerous status epilepticus.
- Adequate hydration: Drink plenty of water during treatment with Taloxa to help prevent the formation of crystalluria (crystals in the urine) and to support proper renal elimination of the drug.
- Suicidal thoughts: A small number of patients treated with antiepileptic medications, including felbamate, have experienced thoughts of self-harm or suicide. If you or someone you are caring for ever has such thoughts, contact your healthcare provider immediately. This risk is monitored as a class effect of all antiepileptic drugs.
- Skin reactions: Severe skin reactions including Stevens-Johnson syndrome, skin blisters, and toxic epidermal necrolysis have been reported rarely. If you develop blisters in the mouth, nose, or eyes, or blisters and peeling of the skin, muscle or joint pain, fever, or rash, contact your doctor immediately.
- Blood monitoring: During treatment, your doctor will schedule frequent blood tests, typically every two weeks, to check your complete blood count and liver function. This monitoring is essential for early detection of any blood or liver abnormalities.
Pregnancy and Breastfeeding
Taloxa should not be used during pregnancy unless it is absolutely necessary and the potential benefit to the mother clearly outweighs the potential risk to the fetus. Animal studies have raised concerns about teratogenic effects, and there is limited human data available. If you are a woman of childbearing potential, you must use an effective method of contraception during treatment and for up to 1 month after stopping treatment.
Importantly, felbamate can reduce the effectiveness of oral contraceptives (birth control pills). Therefore, you should use an alternative, non-hormonal method of contraception or add a barrier method while taking Taloxa. Discuss the most appropriate contraceptive options with your healthcare provider.
If you are pregnant or think you may be pregnant, consult your doctor immediately. Do not stop taking your medication without first discussing it with your doctor, as uncontrolled seizures during pregnancy also pose significant risks to both mother and baby. Your doctor may decide to adjust your treatment.
Breastfeeding is not recommended while taking Taloxa. Felbamate is excreted in breast milk and could potentially harm the nursing infant, particularly by causing blood or liver damage. If you are taking Taloxa and wish to breastfeed, discuss alternative options with your healthcare provider.
Driving and Operating Machinery
Taloxa may cause drowsiness, fatigue, or dizziness. These effects can impair your ability to drive vehicles or operate machinery safely. When Taloxa is given to children and adolescents, be aware that dizziness and drowsiness may occur during activities such as cycling or participating in traffic. Do not drive or operate machinery until you know how this medication affects you. The combination of epilepsy itself and the side effects of antiepileptic drugs means you should exercise particular caution and follow local regulations regarding driving with epilepsy.
How Does Taloxa Interact with Other Drugs?
Drug interactions are an important consideration when using Taloxa, particularly because most patients with refractory epilepsy take multiple antiepileptic drugs simultaneously. Felbamate is both a substrate and an inhibitor of hepatic cytochrome P450 enzymes (particularly CYP3A4 and CYP2C19), which means it can affect the metabolism of many other drugs and its own metabolism can be affected by enzyme inducers and inhibitors.
The most clinically significant interactions occur with other commonly used antiepileptic drugs. When felbamate is added to an existing antiepileptic regimen, or when other drugs are added to or removed from a felbamate-containing regimen, careful monitoring of drug levels and clinical response is essential, and dose adjustments are frequently required.
Major Interactions
| Interacting Drug | Effect | Clinical Action |
|---|---|---|
| Phenytoin | Felbamate increases phenytoin levels by 20–30% through inhibition of CYP2C19; phenytoin decreases felbamate levels by 15–25% | Reduce phenytoin dose by approximately 20% when adding felbamate; monitor phenytoin levels closely |
| Carbamazepine | Felbamate decreases carbamazepine levels but increases the active metabolite (carbamazepine-10,11-epoxide) by up to 50%; carbamazepine decreases felbamate levels by up to 40% | Reduce carbamazepine dose by 20–33% when adding felbamate; monitor for increased side effects from the active metabolite |
| Valproic acid | Felbamate increases valproic acid levels by 25–50% through inhibition of beta-oxidation | Reduce valproic acid dose by approximately 30% when adding felbamate; monitor valproic acid levels |
| Phenobarbital | Felbamate increases phenobarbital levels by approximately 25%; phenobarbital may decrease felbamate levels | Monitor phenobarbital levels; dose reduction of phenobarbital may be necessary |
| Oral contraceptives | Felbamate reduces the effectiveness of hormonal contraceptives through enzyme induction | Use alternative non-hormonal contraception or add a barrier method during treatment and for 1 month after |
Minor Interactions
Felbamate may also interact with other medications that are metabolized by the CYP3A4 enzyme system. If you are taking any other prescription or over-the-counter medications, herbal supplements, or vitamins, inform your healthcare provider. Particular attention should be paid to drugs with narrow therapeutic indices (where small changes in blood levels can cause toxicity or loss of efficacy).
When Taloxa is combined with other antiepileptic medications, patients may notice an increase in side effects, particularly gastrointestinal symptoms (nausea, vomiting), drowsiness, and dizziness. If side effects become troublesome, contact your doctor as dose adjustments of one or more medications may be necessary. Do not adjust doses on your own without medical guidance.
Because felbamate is typically used as add-on therapy in patients already taking other antiepileptic drugs, careful monitoring of all drug levels and clinical response is essential whenever felbamate is started, the dose is changed, or other medications are added or removed from the regimen.
What Is the Correct Dosage of Taloxa?
Always take Taloxa exactly as your doctor has prescribed. Do not change the dose or stop taking the medication without consulting your healthcare provider. The correct dose and dosing interval are determined individually by your doctor based on your condition, body weight, other medications, and response to treatment.
Taloxa is typically taken 2 times daily (every 12 hours) or 3 times daily (every 8 hours). During the first weeks of treatment, the dose is usually increased gradually to minimize side effects and allow your body to adjust. Take the medication at the same times each day. Do not skip any doses, and do not take more than the prescribed dose.
Adults
Adult Dosage (Adjunctive Therapy)
Starting dose: 1,200 mg/day, divided into 2–3 doses. The dose is gradually increased by 600 mg every 1–2 weeks based on clinical response and tolerability.
Usual maintenance dose: 2,400–3,600 mg/day in divided doses.
Maximum recommended dose: 3,600 mg/day.
Note: When felbamate is added, the doses of concomitant antiepileptic drugs (particularly phenytoin, carbamazepine, and valproic acid) usually need to be reduced by 20–33% to prevent toxicity from drug interactions.
Children (Over 4 Years)
Pediatric Dosage (Over 4 Years, Adjunctive Therapy)
Starting dose: 15 mg/kg/day, divided into 2–3 doses.
Dose increase: May be increased by 15 mg/kg/day at weekly intervals.
Usual maintenance dose: 30–45 mg/kg/day in divided doses.
Maximum: 45 mg/kg/day or 3,600 mg/day, whichever is lower.
Elderly
Elderly Patients
Elderly patients may be more susceptible to side effects due to age-related changes in kidney and liver function. Treatment should be initiated at the lower end of the dosing range, with cautious dose increases. Monitoring of renal and hepatic function is particularly important. Your doctor will determine the appropriate dose based on your individual circumstances.
How to Take Taloxa Oral Suspension
Taloxa oral suspension (120 mg/ml) should be prepared and administered as follows:
- Shake the bottle well before each dose to ensure uniform distribution of the suspension.
- Measure the dose using the calibrated 5.0 ml dosing syringe provided in the package. Insert the syringe into the bottle, keep the tip submerged in the liquid, and draw up the prescribed volume by pulling the plunger outward.
- Check the measurement – verify that the correct amount is shown at the bottom of the syringe. If the measurement is incorrect, empty the syringe back into the bottle and repeat.
- Administer the dose by placing the syringe tip in the mouth and pressing the plunger down to deliver the suspension. Swallow the dose.
- Clean the syringe by disassembling it and rinsing both parts with water after each use.
Taloxa can be taken with or without food. The oral suspension should be stored tightly closed and used within 3 months after first opening the bottle.
Missed Dose
If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to make up for a forgotten dose. It is important to return to your normal dosing schedule as soon as possible to maintain consistent drug levels in your blood.
Overdose
If you or someone else takes too much Taloxa, or if a child accidentally ingests the medication, contact your doctor, hospital emergency department, or poison control center immediately for risk assessment and advice. An overdose may require medical monitoring and supportive treatment in a hospital setting.
Do not stop taking Taloxa unless your doctor tells you to. Suddenly discontinuing antiepileptic medications, including felbamate, can lead to an increased risk of seizures, including prolonged seizures (status epilepticus), which can be life-threatening. If your doctor decides to stop Taloxa, the dose will be gradually reduced over time.
What Are the Side Effects of Taloxa?
Like all medications, Taloxa can cause side effects, although not everyone will experience them. Most side effects are mild to moderate and may improve as your body adjusts to the medication. However, some side effects can be serious and require immediate medical attention.
Contact your doctor immediately if you experience any of the following: unusual bleeding or bruising, frequent infections, persistent fatigue, jaundice (yellowing of eyes or skin), unexplained weight loss, persistent vomiting or abdominal pain, blisters in the mouth, nose, or eyes, blisters and peeling of the skin, muscle or joint pain with fever and rash.
Taloxa has been associated with rare cases of serious blood disorders and liver problems that can be life-threatening. This is why regular blood monitoring is mandatory during treatment (see the Warnings section above).
Common
- Weight loss, loss of appetite
- Insomnia (difficulty sleeping)
- Drowsiness, somnolence
- Impaired coordination of muscle movements (ataxia)
- Dizziness
- Headache
- Fatigue, tiredness
- Double vision (diplopia), abnormal vision
- Nausea, vomiting
- Upset stomach, abdominal pain
- Diarrhea
Uncommon
- Hypophosphatemia (abnormally low blood phosphate levels)
- Speech disturbances
- Depression
- Stiffness, rigidity
- Anxiety, restlessness
- Skin rash
- Abnormal gait (walking difficulties)
Rare
- Serious blood count changes including thrombocytopenia (decreased platelets), leukopenia and neutropenia (decreased white blood cells), and anemia (decreased red blood cells); combinations of these or pancytopenia (decrease in all cell types) and aplastic anemia (bone marrow failure) may occur
- Increased seizure frequency
- Anaphylactic shock (severe whole-body allergic reaction)
- Severe hypersensitivity reactions: Stevens-Johnson syndrome, skin blistering, toxic epidermal necrolysis (blisters and peeling of skin and mucous membranes)
- Muscle or joint pain
- Fever
Very Rare
- Constipation
- Urinary crystals (crystalluria)
- Liver problems which may be serious, including fatal hepatic failure
Additional Side Effects in Children and Adolescents
Children and adolescents may experience a similar pattern of side effects as adults. Additionally, upper respiratory tract infections have been frequently observed in pediatric patients, although a causal relationship with felbamate treatment is considered unlikely. Parents and caregivers should be vigilant for any changes in behavior, mood, or physical symptoms and report these to the treating physician promptly.
If you experience any side effects not listed here, or if any side effects become severe or bothersome, contact your healthcare provider. Reporting side effects helps regulatory authorities continuously monitor the benefit-risk balance of medications. In the United States, you can report side effects to the FDA via MedWatch. In Europe, reports can be submitted to national pharmacovigilance authorities.
How Should You Store Taloxa?
Proper storage of Taloxa is important to maintain the medication’s effectiveness and safety. Follow these guidelines carefully:
- Temperature: Store at or below 25°C (77°F). Do not freeze the oral suspension.
- Keep out of reach: Store this medication out of the sight and reach of children to prevent accidental ingestion.
- Expiration date: Check the expiration date on the carton (tablets) or on the carton and label (oral suspension). The expiration date refers to the last day of the stated month. Do not use the medication after this date.
- Oral suspension after opening: Close the bottle tightly after each use. The suspension remains stable for 3 months after first opening the bottle. Note the date of first opening on the label and discard the suspension after 3 months.
- Inspect before use: Do not use Taloxa if you notice any changes in the appearance of the tablets or suspension. Consult your pharmacist or doctor if you have concerns.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired medications to your pharmacy for proper disposal. These measures help protect the environment.
What Does Taloxa Contain?
Active Ingredient
Both formulations contain felbamate as the active substance:
- Taloxa 600 mg tablets: each tablet contains 600 mg felbamate
- Taloxa oral suspension: each ml contains 120 mg felbamate (120 mg/ml)
Inactive Ingredients
Tablets: Pregelatinized starch, microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate. Note: Taloxa tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, consult your doctor before taking this medication. The tablets contain less than 1 mmol (23 mg) sodium per dose, meaning they are essentially sodium-free.
Oral suspension: Sorbitol (E420), glycerol (E422), microcrystalline cellulose with carmellose sodium, simethicone emulsion, saccharin sodium, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), sodium benzoate (E211), polysorbate 80, Prosweet “G” #859 (glycerol (E422), vanillin, ethyl maltol), and purified water.
The oral suspension contains methyl and propyl parahydroxybenzoates (parabens), which may cause allergic reactions in some individuals (possibly delayed). It also contains sorbitol (1.05 g per 5 ml, equivalent to 210 mg/ml), which is a source of fructose. If you have hereditary fructose intolerance, consult your doctor before taking this medication. Sorbitol may cause gastrointestinal discomfort and may have a mild laxative effect. The oral suspension contains sodium benzoate (10 mg per 5 ml).
Packaging
Tablets: Taloxa 600 mg tablets are white, capsule-shaped, scored tablets with the SP logo and “600” on one side. Available in blister packs of 100 tablets (5 blister cards of 20 tablets each).
Oral suspension: Taloxa 120 mg/ml oral suspension is a white to off-white opaque suspension supplied in a 230 ml glass bottle. A CE-marked 5 ml dosing syringe for oral use is included in the package.
Frequently Asked Questions About Taloxa
Taloxa (felbamate) is an antiepileptic medication used to treat Lennox-Gastaut syndrome and other forms of epilepsy that cannot be adequately controlled with other antiepileptic drugs. It is approved for use in adults and children over 4 years of age as adjunctive therapy (used alongside other seizure medications) or as monotherapy in refractory cases. Lennox-Gastaut syndrome is a severe childhood-onset epilepsy characterized by multiple seizure types, and felbamate is particularly effective in reducing atonic seizures (drop attacks) in this condition.
Taloxa has been associated with rare but potentially life-threatening blood disorders (aplastic anemia, estimated at 1 in 3,000–5,000 patients per year) and liver failure (estimated at 1 in 10,000–25,000 patients per year). Regular blood tests, typically every 1–2 weeks, are mandatory to monitor complete blood counts and liver function throughout treatment. Early detection of changes in blood cell counts or liver enzymes allows timely intervention, including dose reduction or discontinuation if necessary.
Yes, felbamate can reduce the effectiveness of oral contraceptives (birth control pills) through hepatic enzyme induction. Women of childbearing potential taking Taloxa should use an alternative, non-hormonal method of contraception (such as an intrauterine device, barrier methods, or other non-hormonal options) or add a barrier method during treatment and for up to 1 month after stopping the medication. Discuss the most appropriate contraceptive options with your healthcare provider.
After first opening the bottle of Taloxa oral suspension, close it tightly and store at or below 25°C (77°F). The suspension is stable for 3 months after opening. It is recommended to note the date of first opening on the label to track this period. After 3 months, any remaining suspension should be discarded. Always shake the bottle well before measuring each dose, and rinse the dosing syringe with water after each use.
Taloxa should not be used during pregnancy unless absolutely necessary and the potential benefit to the mother clearly outweighs the risk to the fetus. If you are pregnant or planning to become pregnant, consult your doctor immediately – do not stop taking your medication without medical advice, as uncontrolled seizures also pose risks. Breastfeeding is not recommended during Taloxa treatment because felbamate is excreted in breast milk and may cause blood or liver damage in the nursing infant. Women of childbearing potential must use effective non-hormonal contraception during treatment and for 1 month after.
No, you should never stop taking Taloxa suddenly without your doctor’s guidance. Abruptly discontinuing any antiepileptic medication, including felbamate, can lead to a significant increase in seizure frequency and severity, including the risk of status epilepticus (prolonged, continuous seizures), which can be life-threatening. If your doctor decides to stop Taloxa, the dose will be gradually tapered over a period of time to minimize this risk.
References
- European Medicines Agency (EMA). Taloxa – Summary of Product Characteristics. Last updated 2023. Available from the EMA product information database.
- U.S. Food and Drug Administration (FDA). Felbatol (felbamate) – Prescribing Information. Revised 2024.
- International League Against Epilepsy (ILAE). Treatment Guidelines for Lennox-Gastaut Syndrome. Epilepsia. 2022;63(8):1866–1889.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. Updated 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023.
- Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Research. 2006;71(2–3):89–101.
- French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Neurology. 2004;62(8):1252–1260.
- Bourgeois BFD. Felbamate. Seminars in Pediatric Neurology. 1997;4(1):3–8.
- Leppik IE. Felbamate. Epilepsia. 1995;36(Suppl 2):S66–S72.
- The FBM Associated Hepatic Failure Registry and the Aplastic Anemia/Pancytopenia Registry. Monitoring of felbamate-associated adverse events. Pharmacoepidemiology and Drug Safety. 2001.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in neurology, epileptology, and clinical pharmacology.
Medical Content
iMedic Neurology Editorial Team – specialist physicians in neurology and epileptology with clinical experience in seizure disorder management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ILAE, and NICE guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and antiepileptic medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.